Insights
Search Results
News Articles
6.04.26
Wilson Sonsini Practices, Attorneys Recognized in 2026 Chambers USA Guide
The 2026 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 44 geography-specific practice categories and named 87 Wilson Sonsini attorneys among the best in their fields. This year, the firm received four new practice area rankings, including in the nationwide National Security and Capital Markets: Convertible Debt categories, and three improved practice area rankings.
Client Highlights
4.17.26
Firm Advises Neurona Therapeutics on Acquisition by UCB
On April 17, 2026, UCB, a global biopharmaceutical company, announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system. Under the terms of the agreement, UCB will pay $650 million upfront and up to $500 million in potential future milestone payments, subject to certain closing conditions. Wilson Sonsini Goodrich & Rosati advised Neurona on the transaction.
Client Highlights
2.02.26
Wilson Sonsini Advises ALX Oncology on Public Offering
On January 30, 2026, ALX Oncology Holdings Inc., a clinical-stage biotechnology company focusing on novel therapies designed to treat cancer and extend patients’ lives, announced the pricing of an underwritten offering of 76,979,112 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,574,120 shares of common stock in the offering. The gross proceeds of the offering are expected to be approximately $150 million before deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. Wilson Sonsini Goodrich & Rosati advised ALX Oncology on the transaction.
Client Highlights
1.08.26
Firm Advises InduPro on Strategic Investment, Research Collaboration with Sanofi
On December 10, 2025, InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, announced a strategic equity investment and research collaboration with Sanofi. Wilson Sonsini Goodrich & Rosati advised InduPro on the transaction.
Client Highlights
1.08.26
Wilson Sonsini Advises InduPro on $950 Million Strategic Collaboration with Eli Lilly
On January 7, 2026, InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, announced a global strategic collaboration and licensing agreement, and equity investment, with Eli Lilly and Company to discover novel oncology treatments using InduPro’s proximity-guided platform. Under the terms of the agreement, InduPro and Eli Lilly will collaborate on up to three targets, for a total deal value of up to approximately $950 million. Wilson Sonsini Goodrich & Rosati advised InduPro on the transaction.
Client Highlights
12.17.25
Wilson Sonsini Advises Hexagon Bio on Multimillion-Dollar Joint Venture with Corteva
On December 16, 2025, Corteva, a global leader in agricultural technology, and Hexagon Bio, a biotechnology company pioneering a new way to discover nature-derived medicine, announced a multimillion-dollar joint venture (JV) to accelerate the development of new crop protection solutions inspired by nature. The JV is the first in the agriculture sector for Hexagon Bio and the first in the pharmaceutical industry for Corteva. Wilson Sonsini Goodrich & Rosati advised Hexagon Bio on the transaction.
The partnership brings together Corteva’s billion-dollar nature-inspired crop protection franchises and bacterial natural product discovery capabilities with Hexagon Bio’s natural-product discovery platform to advance the companies’ respective pipelines across agriculture and human health. Hexagon Bio’s platform combines microbial genetics, artificial intelligence, chemistry, and synthetic biology to identify and characterize novel natural products, uncovering diverse mechanisms not obvious from the chemical structure or conventional techniques and allowing for more efficient molecule discovery.
The Wilson Sonsini team that advised Hexagon Bio on the transaction included Ken Clark, Norm Hovijitra, Aleks Vitomirov, Lance Brady, Christina Poulsen, Adrian Broderick, Sara Pollock, Jacob Morales, Henry Yen, Myra Sutanto Shen, and Rob Sherrill.
For more information, please see the companies’ joint news release.
The partnership brings together Corteva’s billion-dollar nature-inspired crop protection franchises and bacterial natural product discovery capabilities with Hexagon Bio’s natural-product discovery platform to advance the companies’ respective pipelines across agriculture and human health. Hexagon Bio’s platform combines microbial genetics, artificial intelligence, chemistry, and synthetic biology to identify and characterize novel natural products, uncovering diverse mechanisms not obvious from the chemical structure or conventional techniques and allowing for more efficient molecule discovery.
The Wilson Sonsini team that advised Hexagon Bio on the transaction included Ken Clark, Norm Hovijitra, Aleks Vitomirov, Lance Brady, Christina Poulsen, Adrian Broderick, Sara Pollock, Jacob Morales, Henry Yen, Myra Sutanto Shen, and Rob Sherrill.
For more information, please see the companies’ joint news release.
Client Highlights
11.06.25
Wilson Sonsini Advises Azalea Therapeutics on $82 Million Financing
On November 4, 2025, Azalea Therapeutics, a biotechnology company redefining precision genomic medicines in vivo, announced its official launch and completion of $82 million in seed and Series A financing to advance its proprietary Enveloped Delivery Vehicle (EDV) technology. The funding was led by Third Rock Ventures, with participation from RA Capital Management, Yosemite, Sozo Ventures, and select individual investors. Wilson Sonsini Goodrich & Rosati advised Azalea Therapeutics on the transaction.
News Articles
10.01.25
LMG Life Sciences Recognizes Wilson Sonsini, Attorneys in 2025 Guide
On September 30, 2025, LMG Life Sciences announced the 2025 edition of its guide, which identifies and ranks the leading law firms and individuals in the life sciences industry across the United States. The rankings are the result of firm participation in questionnaires, partner interviews to gather market feedback, client surveys, and independent research. LMG Life Sciences has conducted research and published rankings since 2012. This year, six Wilson Sonsini practices and 18 attorneys have been recognized in the guide.
News Articles
6.05.25
2025 Chambers USA Guide Recognizes Wilson Sonsini Practices, Attorneys
The 2025 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 39 geography-specific practice categories and named 86 Wilson Sonsini attorneys among the best in their fields. This year, the firm received three new practice area rankings, including in the Artificial Intelligence category, and four improved practice area rankings.
News Articles
5.30.25
Wilson Sonsini, Attorneys Honored in 2025 IAM Patent 1000
On May 29, 2025, IAM 1000 recognized Wilson Sonsini in the 2025 edition of IAM Patent 1000. The guide honored the firm with three firm rankings and six Wilson Sonsini attorneys received individual recommendations in the rankings.
Client Highlights
5.06.25
Wilson Sonsini Advises Stately Bio on $12 Million Seed Financing
On May 2, 2025, Stately Bio, a start-up developing cell therapies using an ML-powered live-cell imaging platform, emerged from stealth with $12 million in seed financing. The funding was led by AIX Ventures, with participation from Dimension Capital, Foothill Ventures, Village Global, Caffeinated Capital, Mitsui Global Investment, BoxOne Ventures, Axial VC, Jeff Dean (Chief Scientist at Google DeepMind), Jeremy Wertheimer (co-founder of ITA Software), and Tom Berry (co-founder of Carbon Health). The new funding will be used to scale the company’s platform technology and mature its internal pipeline of stem cell-derived therapeutics.